IDH1 Gene Mutation clinical trials at UCSF

1 research study open to eligible people

IDH1 Gene Mutation is a DNA change found in some tumors. A clinical trial is recruiting adolescents and young adults with IDH1/2-mutant gliomas to test the best dose and side effects of BGB-290 and temozolomide treatments. UCSF is conducting this trial.

Showing trials for

  • BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas

    open to eligible people ages 13-25

    This phase I trial studies the side effects and best dose of BGB-290 and temozolomide in treating adolescents and young adults with IDH1/2-mutant grade I-IV glioma that is newly diagnosed or has come back. BGB-290 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving BGB-290 and temozolomide may work better in treating adolescents and young adults with IDH1/2-mutant grade I-IV glioma.

    San Francisco, California and other locations

Our lead scientists for IDH1 Gene Mutation research studies include .

Last updated: